本文已被:浏览 228次 下载 235次
投稿时间:2026-04-01 网络发布日期:2026-09-24
投稿时间:2026-04-01 网络发布日期:2026-09-24
中文摘要: 目的 探讨斯泰度塔单抗联合常规综合治疗对重症破伤风患者的疗效及安全性,为重症破伤风的临床规范化救治提供参考依据。方法 选取2025年10月至2026年3月吉林省人民医院收治的30例Ablett Ⅲ~Ⅳ级重症破伤风患者,按随机数字表法1∶1分为观察组和对照组,每组15例。两组均予清创、镇静解痉、气道管理等常规综合治疗,观察组给予20 mg 斯泰度塔单抗单次臀部肌内注射,对照组给予6 000 u 人破伤风免疫球蛋白(HTIG)多点肌内注射。动态监测患者不同时间节点[包括入院当日用药前(D0)、用药后12 h(Q12)、用药后3 d(D3)、用药后7 d(D7)、用药后28 d(D28)、用药后60 d(D60)]血清破伤风神经毒素(TeNT)中和抗体滴度,记录镇痛镇静药物使用剂量、日均痉挛次数、机械通气时间、住院时间及不良事件发生情况。结果 观察组血清TeNT 中和抗体总体水平更高(P<0.05),事后成对比较显示,D0、Q12、D3及D60时,两组滴度差异无统计学意义(P>0.05);但D7 和D28 时,观察组抗体滴度高于对照组,均值差分别为0.16(-0.01~0.32)IU/mL 和0.19(-0.05~0.34)IU/mL,差异有统计学意义(P<0.05)。观察组瑞芬太尼、丙泊酚、右美托咪定、咪达唑仑使用剂量少于对照组(P<0.05);机械通气时间、ICU 住院时间、总住院时间短于对照组(P<0.05);日均痉挛次数少于对照组[5.63(5.30,7.00)次/d vs 7.55(7.20,8.60)次/d,Z=3.029,P=0.002]。两组各不良事件发生率差异无统计学意义(P>0.05)。结论 斯泰度塔单抗联合常规综合治疗可有效提升重症破伤风患者血清TeNT中和抗体滴度,缓解痉挛症状,减少镇痛镇静药物使用,缩短治疗周期,且安全性良好,该联合治疗可初步作为重症破伤风临床治疗的有效方案。
Abstract:Objective To explore the efficacy and safety of siltartoxatug combined with conventional comprehensive therapy in patients with severe tetanus,so as to provide reference for standardized clinical management of severe tetanus. Methods Thirty patients with severe tetanus(Ablett grades Ⅲ- Ⅳ)admitted to Jilin Province People 's Hospital between October 2025 and March 2026 were enrolled. They were divided into the observation group and the control group at a 1∶1 ratio via random number table,15 cases in each group. Both groups received routine comprehensive interventions including debridement,sedative antispasmodic therapy,and airway management. The observation group was administered with a single gluteal intramuscular injection of 20 mg siltartoxatug,while the control group received multi-site intramuscular injection of 6 000 u human tetanus immunoglobulin(HTIG). Serum tetanus neurotoxin(TeNT)neutralizing antibody titers at serial time points[pre-administration on admission day(D0),12 hours post-administration(Q12),post-administration day 3(D3),day 7(D7),day 28(D28)and day 60(D60)]were dynamically monitored. The dosage of analgesic and sedative agents,average daily number of spasms,duration of mechanical ventilation,length of hospital stays,and incidence of adverse events were recorded. Results The overall serum TeNT neutralizing antibody level in the observation group was significantly higher than that in the control group(P<0.05). Post hoc pairwise comparisons showed no statistically significant difference in antibody titers between the two groups at D0,Q12,D3 and D60(P>0.05). At D7 and D28,the titers in the observation group were significantly higher than those in the control group,with mean differences of 0.16(-0.01 to 0.32)IU/mL and 0.19(-0.05 to 0.34)IU/mL,respectively,and the differences were statistically significant (P<0.05). The dosages of remifentanil,propofol,dexmedetomidine and midazolam used in the observation group were all lower than those in the control group(P<0.05).The duration of mechanical ventilation,intensive care unit stay and total hospital stay in the observation group were shorter than those in the control group(P<0.05). The observation group had fewer mean daily number of spasms than the control group[5.63(5.30,7.00)time/d vs 7.55(7.20,8.60)time/d,Z=3.029,P=0.002]. There was no statistically significant difference in the incidence of adverse events between the two groups(P>0.05). Conclusion Siltartoxatug combined with conventional comprehensive therapy can effectively increase serum TeNT neutralizing antibody titers,relieve spastic symptoms,reduce the consumption of analgesic and sedative,and shorten the treatment course,with satisfactory safety profile. This combined treatment can be initially recommended as an effective regimen for clinical treatment of severe tetanus.
keywords: Siltartoxatug Human tetanus immunoglobulin Severe tetanus Immunotherapy Tetanus neurotoxin
文章编号: 中图分类号:R517.3 文献标志码:A
基金项目:吉林省卫生健康科技能力提升计划项目(2025WS-YA028)
附件
| 作者 | 单位 |
| 张诺 | 1. 长春中医药大学临床医学院,吉林 长春 130000 |
| 董春丽 | 2. 吉林省人民医院重症医学科,吉林 长春 130000 |
| 王永杰 | 2. 吉林省人民医院重症医学科,吉林 长春 130000 |
| Author Name | Affiliation |
| ZHANG Nuo*,DONG Chunli,WANG Yongjie | *Clinical Medical College,Changchun University of Chinese Medicine,Changchun,Jilin 130000,China |
引用文本:
张诺,董春丽,王永杰.斯泰度塔单抗治疗重症破伤风患者的疗效与安全性评价[J].中国临床研究,2026,39(9):1378-1383.
张诺,董春丽,王永杰.斯泰度塔单抗治疗重症破伤风患者的疗效与安全性评价[J].中国临床研究,2026,39(9):1378-1383.
